A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To determine the effectiveness of CP-868,596 + docetaxel, AG-013736 + docetaxel and CP-868,596 + AG-013736 + docetaxel in patients previously treated for non-small cell lung cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Arog Pharmaceuticals, Inc.
• Treatments: Axitinib; Crenolanib; Docetaxel

Criteria

Inclusion Criteria:

• Platinum-pretreated patients with advanced stage IIIb or IV NSCLC

Exclusion Criteria:

• Centrally-located tumors